Machine learning based on metabolomics unveils neutrophil extracellular trap-related metabolic signatures in non-small cell lung cancer patients undergoing chemoimmunotherapy

Table 2 Potential clinical factors correlated with chemoimmunotherapy efficacy in non-small cell lung cancer patients

Factors	PD/SD, n = 62	CR/PR, n = 97	t/χ2/Z	P value
IL-6 in pg/mL	16.38 (0.14, 92.85)	17.93 (0.05, 219.79)	0.616	0.538
IL-8 in pg/mL	146.29 (19.87, 1038.52)	112.19 (15.76, 915.15)	1.986	0.047
PD-L1			2.413	0.035
< 1%	20 (32.3)	35 (36.1)
1%-49%	38 (61.3)	43 (44.3)
> 50%	4 (6.4)	19 (19.6)
NETs in pg/mL	740.63 (28.05, 3128.41)	467.54 (11.36, 2036.62)	2.564	0.011
Neutrophil percent	5.88 (1.93, 10.85)	5.09 (1.35, 13.5)	2.078	0.058
CD3 cell percent	63.03 (28.22, 86.55)	64.30 (29.63, 85.35)	0.533	0.594
CD4 cell percent	35.64 (17.56, 53.86)	37.88 (16.13, 62.02)	1.199	0.231
CD8 cell percent	25.07 (10.25, 64.67)	24.13 (10.28, 46.54)	0.215	0.829
B cell percent	10.88 (0.77, 36.50)	8.96 (0.98, 23.31)	1.831	0.067
NK cell percent	23.89 (5.90, 65.47)	24.79 (6.76, 53.68)	0.496	0.622
NLR	4.14 (2.43, 5.81)	3.13 (2.3, 4.2)	2.551	0.011
NLR grouping			6.947	0.008
≤ 4	32 (51.6)	70 (72.2)
> 4	30 (48.4)	27 (27.8)
Lymphocyte percent	1.53 (0.38, 3.04)	1.56 (0.67, 3.32)	0.457	0.647
Hepatic metastases			1.428	0.232
No	47 (75.8)	81 (83.5)
Yes	15 (24.2)	16 (16.5)
Bone metastasis			2.109	0.146
No	49 (79.0)	85 (87.6)
Yes	13 (21.0)	12 (12.4)
Metastatic sites			1.067	0.302
< 3	42 (67.7)	73 (75.3)
≥ 3	20 (32.3)	24 (24.7)

Data are n (%). CR: Complete response; IL: Interleukin; NETs: Neutrophil extracellular traps; NK: Natural killer; NLR: Neutrophil to lymphocyte ratio; PD: Progressive disease; PR: Partial response; SD: Stable disease.